Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Diabetes Management by Probiotics: Current Knowledge and Future Perspectives Publisher



Homayounirad A1 ; Soroush AR2 ; Khalili L3 ; Norouzipanahi L4 ; Kasaie Z1 ; Ejtahed HS5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Food Science and Technology, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
  2. 2. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Nutrition, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
  4. 4. Department of Midwifery, Tabriz Branch, Islamic Azad University, Tabriz, Iran
  5. 5. Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: International Journal for Vitamin and Nutrition Research Published:2016


Abstract

Diabetes mellitus, a multifactorial disorder, is related to the intestinal microbiota via numerous molecular mechanisms. The vast increase in the prevalence of diabetes and its associated complications requires a natural and safe solution. There is a growing evidence of gut microbiota efficiency in improving insulin resistance, impaired insulin secretion, and metabolic complications in diabetic patients. Probiotics are defined as live microorganisms that, when ingested in adequate amounts, exert health benefits to the host. Probiotics can increase insulin sensitivity and reduce autoimmune responses by modulating intestinal microbiota and decreasing the inflammatory reactions and oxidative stress. Recent evidences show that the intestinal microbiota influences the host through modulating intestinal permeability and mucosal immune response, manipulating eating behaviors by appetite-regulating hormones, including agouti related protein (AgRP), glucagon like peptide-1 (GLP-1) and neuropeptide Y, and controlling gut endocannabinoid (eCB) system which is now believed to be associated with inflammation and diabetes. Moreover, intestinal microbiota control the host metabolism by affecting energy extraction from food and by biochemically converting molecules derived from the host or from gut microbes themselves. Experimental studies and clinical trials support the hypothesis that the modulation of the intestinal microbiota by probiotics, especially Lactobacillus and Bifidobacterium strains may be effective in prevention and management of diabetes. This review will highlight the current evidences in probiotic effectiveness and future prospects for exploring probiotic therapy in prevention and control of diabetes. © 2017 Hogrefe.
Other Related Docs
14. The Role of Probiotics on Controlling Diabetes Mellitus: An Umbrella Review, Journal of Mazandaran University of Medical Sciences (2021)
15. Gut Microbiota in Nonalcoholic Fatty Liver Diseases With and Without Type-2 Diabetes Mellitus, European Journal of Gastroenterology and Hepatology (2021)
16. Lifestyle Alters Gut-Bacteria Function: Linking Immune Response and Host, Best Practice and Research: Clinical Gastroenterology (2017)
17. The Comparison of Food and Supplement As Probiotic Delivery Vehicles, Critical Reviews in Food Science and Nutrition (2016)
18. The Role of Intestinal Microbiota in Cognitive Disorders, Journal of Mazandaran University of Medical Sciences (2021)
20. Gut Microbiota Composition in Obese and Normal Weight Adults in Iran, Journal of Mazandaran University of Medical Sciences (2021)
23. The Landscape of Microbiota Research in Iran; a Bibliometric and Network Analysis, Journal of Diabetes and Metabolic Disorders (2020)
33. Spondyloarthropathies and Gut Microbiota, Ankylosing Spondylitis - Axial Spondyloarthritis: Cellular# Molecular and Environmental Factors (2021)
37. Gut Microbiome and Multiple Sclerosis: New Insights and Perspective, International Immunopharmacology (2020)